Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

55.39 +1.20 (+2.21%)

Streaming Delayed Price Updated: 3:59 PM EST, Mar 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,421,115
Open	54.38
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	54.19
Today's Range	54.32 - 55.39
52wk Range	34.75 - 60.85
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Today 8:45 EST

From Genentech

Via Business Wire

Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity

March 05, 2026

From Genentech

Via Business Wire

Performance

YTD	+7.7%	+7.7%
1 Month	-2.1%	-2.1%
3 Month	+14.9%	+14.9%
6 Month	+29.6%	+29.6%
1 Year	+30.4%	+30.4%

More News

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

March 02, 2026

From Genentech

Via Business Wire

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

February 27, 2026

Via MarketMinute

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

Via MarketMinute

Worried About Tariffs? Buy 2 Vanguard Index Funds That Are Beating the S&P 500 in 2026. ↗

February 26, 2026

Via The Motley Fool

FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia

February 20, 2026

From Genentech

Via Business Wire

FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer

February 20, 2026

From Genentech

Via Business Wire

Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer

February 19, 2026

Via MarketMinute

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

Via MarketMinute

Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗

February 16, 2026

Via The Motley Fool

Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease

February 16, 2026

From Genentech

Via Business Wire

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

Via Finterra

Is Now a Good Time to Revisit International ETFs Like SCHF? ↗

February 11, 2026

Via The Motley Fool

Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗

February 10, 2026

Via The Motley Fool

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Via Finterra

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

February 07, 2026

From Genentech

Via Business Wire

Harvard’s PopEVE AI Cracks the Code of Rare Diseases: Ending the ‘Diagnostic Odyssey’ for Millions

February 06, 2026

Via TokenRing AI

AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months

February 06, 2026

Via TokenRing AI

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

February 06, 2026

Via MarketMinute

The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance

February 06, 2026

Via Finterra

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

Via Finterra

These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys? ↗

February 05, 2026

Via The Motley Fool

Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences

January 28, 2026

Via MarketMinute

Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 27, 2026

Via MarketMinute

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?

Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.

What exchange does Roche Holding AG Basel American Depositary Shares trade on?

Roche Holding AG Basel American Depositary Shares trades on the OTC Traded

What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?

The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded

What is the current price of Roche Holding AG Basel American Depositary Shares?

The current price of Roche Holding AG Basel American Depositary Shares is 55.39

When was Roche Holding AG Basel American Depositary Shares last traded?

The last trade of Roche Holding AG Basel American Depositary Shares was at 03/06/26 03:59 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.